Lipoprotein(a) as well as two oxidized phospholipids (OxPLs) are all associated with multivessel coronary artery disease detected on angiography and also linked to a higher risk of major adverse ...

An ribonucleic acid (RNA) inhibitor, olpasiran (Amgen), which has shown it can lower lipoprotein(a) [Lp(a)] levels in patients with cardiovascular disease (CVD), has demonstrated in a phase 2 trial ...

Analysis could lead to future therapies to prevent deadly cardiac events. The RNA inhibitor olpasiran significantly reduces a type of "bad cholesterol" that's associated with a high risk of ...

Olpasiran leads to significant and sustained reduction in oxidized phospholipids on apolipoprotein B. HealthDay News — Olpasiran, a small interfering RNA, which blocks lipoprotein(a) (Lp[a]) ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. A novel agent demonstrated a dose-dependent relationship ...

Higher concentrations of low-density lipoprotein (LDL) that has been modified by oxidation is associated with an increased incidence of abdominal obesity, high fasting glucose levels and high ...

AMSTERDAM--(BUSINESS WIRE)--VectorY Therapeutics, a biotech company focusing on the development of innovative gene therapy approaches for the treatment of neurodegenerative and muscular disorders ...

We determine how cells respond to external stimuli and transduce these signals into functional responses. We explore the biology of the vascular system, particularly the rapid trafficking of ...

The pattern of valvular heart disease in India is shifting. Degenerative tricuspid aortic stenosis now accounts for 58.1% of acquired isolated aortic stenosis (AS) cases (mean age 63.2 ± ...

The RNA inhibitor olpasiran significantly reduces a type of “bad cholesterol” that’s associated with a high risk of cardiovascular events, according to results from an analysis by a Mount Sinai ...